Acrivon Therapeutics Target Price

See how ACRV's target price trends over time vs similar companies.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.96

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2024-11-14	BMO CapitalEtzer Darout	$27	1277.6% upside
2024-09-16	BMO CapitalEtzer Darout	$28	1328.6% upside
2024-08-13	OppenheimerMatthew Biegler	$18	818.4% upside
2024-05-14	OppenheimerMatthew Biegler	$21	971.4% upside
2024-05-14	H.C. WainwrightEmily Bodnar	$22	1022.4% upside
2024-05-14	BMO CapitalEtzer Darout	$25	1175.5% upside
2024-04-25	Piper SandlerJoseph Catanzaro	$30	1430.6% upside
2024-04-25	JMP SecuritiesSilvan Tuerkcan	$17	767.3% upside
2024-03-28	H.C. WainwrightEmily Bodnar	$20	920.4% upside
2022-12-12	Jefferies	$17	767.3% upside
2022-12-11	Piper SandlerJoseph Catanzaro	$25	1175.5% upside

Acrivon Therapeutics (ACRV) FAQ

Stockcircle tracks target price for Acrivon Therapeutics (ACRV), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Acrivon Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main ACRV overview so you can move from this figure to the surrounding analysis quickly.